Clinical features of hypertension in patients with normal weight and overweight




arterial hypertension, overweight, obesity, coronary heart disease, dyscholesterolemia


Objective of the study: То determine the clinical features of arterial hypertension in overweight patients.

Materials and methods. There were 170 patients included in the study and depending on body weight were divided into two groups: group I – 86 patients with normal body weight and group II – 84 patients with overweight. In our work we calculated the proportion of patients with abdominal obesity and also analyzed concomitant pathology according to the available medical documentation and anamnesis.

Results. There were slightly more women in the two groups. Comparing the data of office measurement of systolic and diastolic blood pressure in patients with hypertension with normal weight and overweight didn’t show significant differences. The most significant association was observed between patients with overweight and nonalcoholic fatty liver disease (objective data (OD) 3.25; 95% confidence interval (CI) 1.55–5.13) and with impaired glucose tolerance (OR 3.54; 95% CI 1.12–5.68). The percentage of patients with dyscholesterolemia was also statistically higher, although slightly lower than in previous cases (OD 2.61; 95% CI 1.05–3.87) and with gastroesophageal reflux disease (OD 3.14; 95% CI 1.56–5.99). A direct correlation was found between patients with abdominal obesity and the presence of gastroesophageal reflux disease (r = 0.56, p < 0.01), dyscholesterolemia (r = 0.53, p < 0.05) and with diabetes (r = 0.45, p < 0.05). In addition, patients who smoked significantly more often had coronary heart disease (p = 0.044).

Conclusions. The article summarizes information on the clinical features of arterial hypertension in overweight patients. The prevalence of hypertension among the adult population is 30-45%, with overweight and obesity continuing to occupy leading positions among young and mature people in the developed world and in middle-income countries. Determining the features of the course, duration of the disease, the distribution between stage and degree in this category of patients will help to develop optimal algorithms for patient management.

Author Biographies

V.I. Bulda, Educational and Scientific Centre «Institute of Biology and Medicine», Taras Shevchenko National University of Kyiv, Kyiv

MD, professor, head of the Department of Internal Medicine

I.O. Berdnyk, Educational and Scientific Centre «Institute of Biology and Medicine», Taras Shevchenko National University of Kyiv, Kyiv

PhD, assistant, Department of Internal Medicine

O.V. Barabanchyk, Educational and Scientific Centre «Institute of Biology and Medicine», Taras Shevchenko National University of Kyiv, Kyiv

PhD, associate professor, Department of Internal Medicine

I.O. Rodionova, Educational and Scientific Centre «Institute of Biology and Medicine», Taras Shevchenko National University of Kyiv, Kyiv

PhD, associate professor, Department of Internal Medicine


  1. Mills KT, Stefanescu А, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020 Apr;16(4):223-37. doi: 10.1038/s41581-019-0244-2
  2. Pan H, Hibino M, Kobeissi E, Aune D. Blood pressure, hypertension and the risk of sudden cardiac death: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2020 May 35(5):443-54. doi:10.1007/s10654-019-00593-4
  3. Johnson-Mann CN, Cupka JS, Ro A, et al. A Systematic Review on Participant Diversity in Clinical Trials-Have We Made Progress for the Management of Obesity and Its Metabolic Sequelae in Diet, Drug, and Surgical Trials. J Racial Ethn Health Disparities. 2023 10(6):3140-9. doi:10.1007/s40615-022-01487-0
  4. Noce A, Daniele N. The “weight” of obesity on arterial hypertension. Understanding the Molecular Crosstalk in Biological Processes. 2019 Sep. doi:10.5772/INTECHOPEN.87774
  5. Martyniak A, Tomasik PJ. A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2022. 13,1 16. 21 Dec. doi:10.3390/diagnostics13010016
  6. Kahlon T, Carlisle S, Otero Mostacero D, et al. Angiotensinogen: More Than its Downstream Products: Evidence From Population Studies and Novel Therapeutics. JACC. Heart Failure. 2022; 10:699-713. doi:10.1016/j.jchf.2022.06.005
  7. Liu G, Hu Y, Zong G, et al. Smoking cessation and weight change in relation to cardiovascular disease incidence and mortality in people with type 2 diabetes: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Feb;8(2):125-33. doi:10.1016/S2213-8587(19)30413-9
  8. Al-Salameh A, Bouzegaoui NE, Saraval-Gross M, et al. Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. Ann Endocrinol (Paris). 2023 Feb; 84(1):57-68. doi:10.1016/j.ando.2022.09.023
  9. Liao LN, Li TC, Yeh CC, et al. Risk prediction of nephropathy by integrating clinical and genetic information among adult patients with type 2 diabetes Acta Diabetol. 2023 Mar; 60(3):413-24. doi:10.1007/s00592-022-02017-4
  10. Arnotti K, Bamber MD, Brewer V, et al. Dietary interventions and blood pressure in overweight or obese individuals: A systematic review and meta-analysis. Clin Nutr. 2022 Apr;41(4):1001-12. doi:10.1016/j.clnu.2021.06.003
  11. Amiri-Dashatan N, Koushki M, Hosseini H, et al. Association between circulating visfatin and pre-eclampsia: a systematic review and meta-analysis. Journal Matern Fetal Neonatal Med. 2022;35(13):2606-18. doi:10.1080/14767058.2020.1789581
  12. McDaniel CC, Kavookjian J, Whitley HP. Telehealth delivery of motivational interviewing for diabetes management: A systematic review of randomized controlled trials. Patient Educ Counsel. 2022;105(4):805-20. doi:10.1016/j.pec.2021.07.036
  13. Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35(1):4-16. doi:10.1038/hr.2011.173.
  14. Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol. 2021;20(1):170. Published 2021 Aug 19. doi:10.1186/s12933-021-01356-w
  15. Shin MK, Eraso CC, Mu YP, et al. Leptin induces hypertension acting on transient receptor potential Melastatin 7 channel in the carotid body. Circ Res. 2019 Nov;125(11):989-1002. doi: 10.1161/CIRCRESAHA.119.315338
  16. Sherwood A, Hill LaBK, Blumenthal JA, Hinderliter AL, et al. The effects of ambulatory blood pressure monitoring on sleep quality in men and women with hypertension: dipper vs. nondipper and race differences. Am J Hypertens. 2019 Jun;32(1):54-60. doi: 10.1093/ajh/hpy138
  17. Spence JD, Rayner BL. Hypertension in blacks: individualized therapy based on renin/ aldosterone phenotyping. Hypertension. 2018 Aug;72(2):263-9. doi: 10.1161/HYPERTENSIONAHA.118.11064
  18. Pugliese NR, Masi S, Taddei S. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail Rev. 2020 Jan; 25(1):31-42. doi: 10.1007/s10741-019-09855-5
  19. Cruz-Lopez EO, Uijl E, Danser AHJ. Perivascular Adipose Tissue in Vascular Function: Does Locally Synthesized Angiotensinogen Play a Role? J Cardiovasc Pharmacol. 2021 Dec 1;78 (Suppl 6):S53-S62. doi:10.1097/FJC.0000000000001027
  20. White MC, Fleeman R, Arnold ACl. Sex differences in the metabolic effects of the renin-angiotensin system. Biol Sex Differ. 2019 Jul 1;10:31. doi:10.1186/s13293-019-0247-5
  21. Yiannikouris F, Gupte M, Putnam K, et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension. 2012;60(6):1524-1530. doi:10.1161/HYPERTENSIONAHA.112.192690.
  22. Tashchuk VK. New data on the effectiveness of beta-blockers in the treatment of hypertension. HYPERTENSION. 2019 Feb;1(63):35-37. doi:10.22141/2224-1485.1.63.2019.162952
  23. Khanna D, Peltzer C, Kahar P, Parmar MS. Body Mass Index (BMI): A Screening Tool Analysis. Cureus. 2022;14(2):e22119. doi:10.7759/cureus.22119
  24. Alencar AKN, Wang H, Oliveira GMM, et al. Crossroads between Estrogen Loss, Obesity, and Heart Failure with Preserved Ejection Fraction. Arq Bras Cardiol. 2021 Dec; 117(6):1191-201. doi:10.36660/abc.20200855
  25. Powell-Wiley TM et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010. doi:10.1161/CIR.0000000000000973
  26. German CA, Baum SJ, Ferdinand KC, et al. Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology. Am J Prev Cardiol. 2022 Nov 16; 12:100432. doi:10.1016/j.ajpc.2022.100432
  27. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020 Mar;16(3):177-89. doi:10.1038/s41574-019-0310-7




How to Cite

Bulda, V., Berdnyk, I., Barabanchyk, O., & Rodionova, I. (2024). Clinical features of hypertension in patients with normal weight and overweight. REPRODUCTIVE ENDOCRINOLOGY, (71), 104–108.



Interdisciplinary problems